PARP抑制剂治疗子宫内膜癌的研究进展

doi:10.12092/j.issn.1009-2501.2026.04.013

摘要/Abstract

摘要：

子宫内膜癌（endometrial cancer，EC）是全球第二常见的妇科恶性肿瘤。子宫内膜癌的常规治疗方案是手术治疗为主，辅以放射治疗、化学治疗和激素等综合治疗。在子宫内膜癌早期，多数患者无明显阳性体征，就诊时多为晚期，常规治疗方案对于晚期或复发性子宫内膜癌患者预后不佳。因此，临床迫切需要新的治疗方法以改善子宫内膜癌患者的预后。随着分子生物学技术的进步，分子靶向治疗成为研究焦点。聚ADP-核糖聚合酶（poly ADP-ribose polymerase，PARP）抑制剂作为新兴的靶向治疗药物，可通过合成致死效应抑制子宫内膜癌的发展。本文将综述PARP抑制剂在治疗子宫内膜癌中的潜能，以期为子宫内膜癌临床治疗提供新策略。

关键词: PARP抑制剂, 子宫内膜癌, 治疗机制, 联合使用, 预后

Abstract:

Endometrial cancer (EC) is the second most common gynecological malignancy worldwide. The standard treatment for endometrial cancer primarily involves surgical intervention, supplemented by radiotherapy, chemotherapy, and hormonal therapies as part of a comprehensive treatment approach. In the early stages of endometrial cancer, most patients exhibit no significant positive signs, and they often present at advanced stages, leading to poor prognoses with standard treatment regimens for advanced or recurrent endometrial cancer. Therefore, there is an urgent clinical need for new therapeutic methods to improve the prognosis of patients with endometrial cancer. With advancements in molecular biology techniques, molecular targeted therapy has become a focal point of research. PARP inhibitors, as emerging targeted therapeutic agents, inhibit the progression of endometrial cancer through a synthetic lethality effect. This article will review the potential of PARP inhibitors in the treatment of endometrial cancer, with the hope of providing new strategies for clinical management of the disease.

Key words: PARP inhibitors, endometrial cancer, therapeutic mechanism, combination use, prognosis

中图分类号:

贺寿艳, 刘敏俊, 万聪, 谭布珍. PARP抑制剂治疗子宫内膜癌的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(4): 536-542.

Shouyan HE, Minjun LIU, Cong WAN, Buzhen TAN. Research progress of PARP inhibitors therapy for endometrial cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 536-542.

图/表 2

参考文献 40

1	Azadehrah M, Vosoogh S, Azadehrah M. The roles and therapeutic applications of cytokines in endometrial cancer[J]. J Reprod Immunol, 2022, 152, 103652. doi: 10.1016/j.jri.2022.103652
2	Tang YH, Lin CY, Lai CH. Development of new cancer treatment by identifying and focusing the genetic mutations or altered expression in gynecologic cancers[J]. Genes (Basel), 2021, 12 (10): 1586.
3	Merkuryev AV, Egorov VV. Role of PARP-1 structural and functional features in PARP-1 inhibitors development[J]. Bioorg Chem, 2025, 156, 108188. doi: 10.1016/j.bioorg.2025.108188
4	Elkatary RG, El Beltagy HM, Abdo VB, et al. Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice[J]. Environ Toxicol Pharmacol, 2023, 103, 104261. doi: 10.1016/j.etap.2023.104261
5	于蕾, 杨清, 毕芳芳. PARP-1在子宫内膜样腺癌中的表达[J]. 现代肿瘤医学, 2013, 21 (4): 849- 52. doi: 10.3969/j.issn.1672-4992.2013.04.59
6	Kacperczyk-Bartnik J, Bartnik P, Goławski K, et al. Plasma and peritoneal poly (ADP-Ribose) polymerase levels in patients with endometriosis[J]. Biomedicines, 2022, 10 (10): 2451. doi: 10.3390/biomedicines10102451
7	Kaur SD, Chellappan DK, Aljabali AA, et al. Recent advances in cancer therapy using PARP inhibitors[J]. Med Oncol, 2022, 39 (12): 241. doi: 10.1007/s12032-022-01840-7
8	Pei X, Mladenov E, Soni A, et al. PTEN loss enhances error-prone DSB processing and tumor cell radiosensitivity by suppressing RAD51 expression and homologous recombination[J]. Int J Mol Sci, 2022, 23 (21): 12876. doi: 10.3390/ijms232112876
9	Piha-Paul SA, Tseng C, Leung CH, et al. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations[J]. NPJ Precis Oncol, 2024, 8 (1): 166. doi: 10.1038/s41698-024-00634-6
10	Janzen DM, Paik DY, Rosales MA, et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo[J]. Mol Cancer Ther, 2013, 12 (12): 2917- 2928. doi: 10.1158/1535-7163.MCT-13-0572
11	Madariaga A, Garg S, Tchrakian N, et al. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma[J]. Nat Commun, 2023, 14 (1): 1452. doi: 10.1038/s41467-023-37084-w
12	Martorana F, Da Silva LA, Sessa C, et al. Everything comes with a price: the toxicity profile of DNA-damage response targeting agents[J]. Cancers (Basel), 2022, 14 (4): 1014.
13	Hage Chehade C, Gebrael G, Sayegh N, et al. A pan-tumor review of the role of poly (adenosine diphosphate ribose) polymerase inhibitors[J]. CA Cancer J Clin, 2025, 75 (2): 141- 167.
14	Gong X, Liu C, Tang H, et al. Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs[J]. Front Oncol, 2024, 14, 1460412. doi: 10.3389/fonc.2024.1460412
15	郑小卫, 沈源明, 张英丽, 等. 多腺苷二磷酸核糖聚合酶抑制剂不良反应管理指导意见[J]. 浙江大学学报(医学版), 2022, 51 (6): 765- 774. doi: 10.3724/zdxbyxb-2022-0284
16	Zhang X, Huang P, Wang L, et al. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma[J]. Cell Death Dis, 2022, 13 (6): 558. doi: 10.1038/s41419-022-04982-8
17	Wang R, Liu Y, Liu M, et al. Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies[J]. Int J Pharm, 2025, 669, 125028. doi: 10.1016/j.ijpharm.2024.125028
18	Wang J, Li H, He G, et al. Discovery of novel dual poly (ADP-ribose) polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy[J]. J Med Chem, 2020, 63 (1): 122- 139. doi: 10.1021/acs.jmedchem.9b00622
19	Paraghamian SE, Qiu J, Hawkins GM, et al. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer[J]. Cancer Biol Ther, 2023, 24 (1): 2202104. doi: 10.1080/15384047.2023.2202104
20	Bhamidipati D, Haro-Silerio JI, Yap TA, et al. PARP inhibitors: enhancing efficacy through rational combinations[J]. Br J Cancer, 2023, 129 (6): 904- 916. doi: 10.1038/s41416-023-02326-7
21	Zhang A, Zhang L, Xie X, et al. Inhibition of ATM with KU-55933 sensitizes endometrial cancer cell lines to olaparib[J]. Onco Targets Ther, 2023, 16, 1061- 1071. doi: 10.2147/OTT.S426923
22	Zhu Y, Liu K, Zhu H. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis[J]. Int J Gynecol Cancer, 2024, 34 (3): 319- 328. doi: 10.1016/j.ijgc.2025.101680
23	Yi M, Niu M, Xu L, et al. Regulation of PD-L1 expression in the tumor microenvironment[J]. J Hematol Oncol, 2021, 14 (1): 10. doi: 10.1186/s13045-020-01027-5
24	Silk T, Hacker KE, Growdon W, et al. The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025[J]. Curr Opin Obstet Gynecol, 2025, 37 (1): 22- 29. doi: 10.1097/GCO.0000000000001004
25	Konstantinopoulos PA, Gockley AA, Xiong N, et al. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer[J]. JAMA Oncol, 2022, 8 (9): 1317- 1322. doi: 10.1001/jamaoncol.2022.2181
26	Post C CB, Westermann AM, Boere IA, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)[J]. Gynecol Oncol, 2022, 165 (2): 223- 229. doi: 10.1016/j.ygyno.2022.02.025
27	van de Ven AL, Tangutoori S, Baldwin P, et al. Nanoformulation of olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation[J]. Mol Cancer Ther, 2017, 16 (7): 1279- 1289. doi: 10.1158/1535-7163.MCT-16-0740
28	Wang J, Xing W, Lin Y, et al. Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma[J]. J Clin Lab Anal, 2022, 36 (5): e24435. doi: 10.1002/jcla.24435
29	Lesueur P, Chevalier F, Austry JB, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies[J]. Oncotarget, 2017, 8 (40): 69105- 69124. doi: 10.18632/oncotarget.19079
30	Duan M, Leng S, Mao P. Cisplatin in the era of PARP inhibitors and immunotherapy[J]. Pharmacol Ther, 2024, 258, 108642. doi: 10.1016/j.pharmthera.2024.108642
31	Erratum: Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial [J]. J Clin Oncol, 2024, 42(27): 3262.
32	Murakami K, Takamura S, Kakimi K, et al. Tumor immunology and immunotherapy for endometrial cancer[J]. Expert Opin Investig Drugs, 2025, 34 (1/2): 37- 48.
33	Di Dio C, Bogani G, Di Donato V, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma[J]. Gynecol Oncol, 2023, 169, 27- 33. doi: 10.1016/j.ygyno.2022.11.031
34	Piffoux M, Leary A, Follana P, et al. Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial[J]. Nat Commun, 2025, 16 (1): 1821. doi: 10.1038/s41467-025-56914-7
35	Joly F, Leary A, Ray-Coquard I, et al. Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial[J]. Nat Commun, 2025, 16 (1): 7950. doi: 10.1038/s41467-025-62678-x
36	王梦琦, 杨敬敬, 王文桃. 多腺苷二磷酸核糖聚合酶抑制剂联合化疗在晚期子宫内膜癌治疗中的应用价值[J]. 癌症进展, 2021, 19 (13): 1371- 1373+85. doi: 10.11877/j.issn.1672-1535.2021.19.13.20
37	Kuznicki ML, Mallen A, Ha K, et al. Prognostic features of endometrial cancer metastasis to the central nervous system[J]. PLoS One, 2022, 17 (8): e0268794. doi: 10.1371/journal.pone.0268794
38	Wang Q, Zhang F, Gao H, et al. Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report[J]. Ann Palliat Med, 2021, 10 (1): 818- 827. doi: 10.21037/apm-21-113
39	Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer[J]. Nat Rev Clin Oncol, 2011, 8 (5): 302- 306. doi: 10.1038/nrclinonc.2011.42
40	Bai YR, Yang WG, Jia R, et al. The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer[J]. Med Res Rev, 2025, 45 (1): 214- 273. doi: 10.1002/med.22069

Drug	Company	Progress	Time of first approval	Time of approval in China	Indication
Olaparib	AstraZeneca/ MSD	marketed	2014-12	2018-08	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.first-line maintenance therapy for advanced ovarian cancer with BRCA1/2mutation; 3.BRCAmutation and previous treatment failure of denervation-resistant prostate; 4.Combined with bevacizumab for first-line maintenance treatment of HRD-positive ovarian cancer.
Rukapani	Clovis	marketed	2016-12	/	/
Niraparib	GSK/Zai Lab	marketed	2017-03	2019-12	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.First-line maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Taprazopanib	Pfizer	marketed	2018-10		/
Fluzoparib	Heng Rui/ Hansoh	marketed	2020-12	2020-12	1.Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations; 2.Maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Pamiparib	BeOne Medicines Ltd	marketed	2021-04	2021-04	Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations.
Senapari	Impact	NDA	/	/	First-line maintenance therapy for advanced ovarian cancer.

Drug	Company	Progress	Time of first approval	Time of approval in China	Indication
Olaparib	AstraZeneca/ MSD	marketed	2014-12	2018-08	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.first-line maintenance therapy for advanced ovarian cancer with BRCA1/2mutation; 3.BRCAmutation and previous treatment failure of denervation-resistant prostate; 4.Combined with bevacizumab for first-line maintenance treatment of HRD-positive ovarian cancer.
Rukapani	Clovis	marketed	2016-12	/	/
Niraparib	GSK/Zai Lab	marketed	2017-03	2019-12	1.Maintenance therapy for platinum-sensitive recurrent ovarian cancer; 2.First-line maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Taprazopanib	Pfizer	marketed	2018-10		/
Fluzoparib	Heng Rui/ Hansoh	marketed	2020-12	2020-12	1.Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations; 2.Maintenance therapy for platinum-sensitive recurrent ovarian cancer.
Pamiparib	BeOne Medicines Ltd	marketed	2021-04	2021-04	Third-line treatment of platinum-sensitive recurrent ovarian cancer with germline BRCA mutations.
Senapari	Impact	NDA	/	/	First-line maintenance therapy for advanced ovarian cancer.

[1]	俞家旺, 李国梅, 黄昌保, 唐宁, 鲁卫华, 周锋. 皖南地区急性有机磷农药中毒患者预后预测的Nomogram模型研究[J]. 中国临床药理学与治疗学, 2026, 31(4): 460-466.
[2]	曾茜敏, 赵洁珺, 席亚明. 多发性骨髓瘤免疫麻痹的研究现状[J]. 中国临床药理学与治疗学, 2026, 31(4): 561-567.
[3]	宋聪, 高敬林, 班峰, 孟萌, 王明霞. PARP抑制剂在脑胶质瘤治疗中的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(9): 1281-1289.
[4]	丁勤, 杨汝薇, 张声南, 阳国平, 裴奇. 时间-事件分析在评价抗多重耐药革兰阴性菌感染药物疗效中的应用[J]. 中国临床药理学与治疗学, 2025, 30(7): 998-1008.
[5]	许婷婷, 汪万杰, 鲍静, 夏瑞祥. NLRC4介导的炎症小体通路与多发性骨髓瘤的关系及治疗前景[J]. 中国临床药理学与治疗学, 2025, 30(4): 501-508.
[6]	张立仪, 郭紫芬. 孕激素治疗子宫内膜癌研究进展[J]. 中国临床药理学与治疗学, 2024, 29(2): 230-235.
[7]	王梦娇, 高超, 王涛, 张倩, 文娟, 吕冬梅, 胡丽丽. CDA C435T基因多态性显著延长吉西他滨治疗晚期非小细胞肺癌远期疗效[J]. 中国临床药理学与治疗学, 2024, 29(12): 1337-1343.
[8]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[9]	周晶, 周琛, 廖珂, 邱爱林, 董巍檑, 郭紫芬. 孕激素受体基因G1978T 多态性与子宫内膜癌的相关性研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 400-406.
[10]	黄凯歌, 许勤华, 王伟. 血糖、血钙对急性重症胰腺炎患者预后影响的交互作用及预测效能研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1227-1234.
[11]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[12]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[13]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[14]	郑莹, 张玲, 姚丽, 王乾合, 朱克祥. 聚腺苷二磷酸-核糖聚合酶抑制剂在胰腺癌中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 108-115.
[15]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.